FDA Approves New Cystic Fibrosis Drug Combo | IUK Med Online
Sunday, February 25, 2018
Home Medical News FDA Approves New Cystic Fibrosis Drug Combo

FDA Approves New Cystic Fibrosis Drug Combo

3
0
SHARE


Medpage Today

FDA Approves New Cystic Fibrosis Drug Combo

Symdeko approved for patients with specific CFTR mutations

MedpageToday

  • by Contributing Writer

The FDA approved a third disease-modifying cystic fibrosis drug product from Vertex Pharmaceuticals to treat the underlying cause of the disease, the company announced Monday.

To be sold as Symdeko, it’s a two-tablet product combining ivacaftor (Kalydeco) with a new agent called tezacaftor. One tablet, to be taken in the morning, contains both drugs; the second contains ivacaftor only and is to be taken in the evening. The product was approved for patients 12 and older who have two copies of the F508del mutation in the CFTR gene or some other mutation that responds to tezacaftor/ivacaftor.

In a press release, the company announced that it would begin shipping Symdeko to pharmacies across the United States this week.

Results from two company-sponsored phase II studies showed the newly approved, combination treatment to be associated with statistically significant and and clinically meaningful improvements in lung function and other measures of disease, with a favorable safety profile in CF patients with two copies of the F508del mutation or one F508del mutation and one mutation resulting in residual CFTR function.

The EVOLVE and the EXPAND study findings were published last November in the New England Journal of Medicine.

2018-02-13T14:26:38-0500
Comments

Accessibility Statement

At MedPage Today, we are committed to ensuring that individuals with disabilities can access all of the content offered by MedPage Today through our website and other properties. If you are having trouble accessing www.medpagetoday.com, MedPageToday's mobile apps, please email legal@ziffdavis.com for assistance. Please put "ADA Inquiry" in the subject line of your email.

Medpage Today

FDA Approves New Cystic Fibrosis Drug Combo

Symdeko approved for patients with specific CFTR mutations

MedpageToday

  • by Contributing Writer

The FDA approved a third disease-modifying cystic fibrosis drug product from Vertex Pharmaceuticals to treat the underlying cause of the disease, the company announced Monday.

To be sold as Symdeko, it's a two-tablet product combining ivacaftor (Kalydeco) with a new agent called tezacaftor. One tablet, to be taken in the morning, contains both drugs; the second contains ivacaftor only and is to be taken in the evening. The product was approved for patients 12 and older who have two copies of the F508del mutation in the CFTR gene or some other mutation that responds to tezacaftor/ivacaftor.

In a press release, the company announced that it would begin shipping Symdeko to pharmacies across the United States this week.

Results from two company-sponsored phase II studies showed the newly approved, combination treatment to be associated with statistically significant and and clinically meaningful improvements in lung function and other measures of disease, with a favorable safety profile in CF patients with two copies of the F508del mutation or one F508del mutation and one mutation resulting in residual CFTR function.

The EVOLVE and the EXPAND study findings were published last November in the New England Journal of Medicine.

2018-02-13T14:26:38-0500
Comments

Accessibility Statement

At MedPage Today, we are committed to ensuring that individuals with disabilities can access all of the content offered by MedPage Today through our website and other properties. If you are having trouble accessing www.medpagetoday.com, MedPageToday's mobile apps, please email legal@ziffdavis.com for assistance. Please put "ADA Inquiry" in the subject line of your email.



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here